Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Piper Sandler has reaffirmed its Overweight rating on Iovance Biotherapeutics (NASDAQ:IOVA), increasing its price target from $18.00 to $19.00. The adjustment reflects a potential 28.81% upside from the current share price of $14.75. Iovance Biotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing personalized T-cell therapies for solid tumor cancers and is preparing for potential U.S. regulatory approvals and commercialization.
March 14, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains Overweight rating on Iovance Biotherapeutics, raising price target to $19. This reflects a significant potential upside from the current price.
The reaffirmation of the Overweight rating and the increase in price target by Piper Sandler are strong positive signals for Iovance Biotherapeutics. Given the company's focus on developing innovative cancer treatments and the potential for U.S. regulatory approvals, this analyst endorsement could significantly boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100